Around 100 Yolo County residents including indigenous community members, and UC Davis students and professors filled the main ...
Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel ...
Good morning, everyone, and welcome to Ligand's 2025 Investor Day. I'm Melanie Herman, Head of Investor Relations for Ligand. And on behalf of our entire team, I'd like to thank you for taking the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback